Poseida Therapeutics Presents New Phase 1 Data at AACR 2024

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

Related Keywords

San Diego , California , United States , American , Syed Rizvi , Rajesh Belani , Bhagirathbhai Dholaria , Poseida Therapeutics Inc , Vanderbilt Ingram Cancer Center , Drug Administration , Prnewswire Poseida Therapeutics Inc , Nasdaq , Clinical Development , American Association For Cancer Research , Linkedin , American Association , Cancer Research , Annual Meeting , Associate Professor , Chief Medical Officer , Subgroup Data , Optimizing Lymphodepletion , Solid Tumors Treated , Investigational Allogeneic , B Cell Maturation Antigen , Relapsed Refractory Multiple Myeloma , Patients Following Progression , Poseida Therapeutics , Clinical Trials , Multiple Myeloma Patients , Achieve Adequate Lymphodepletion Necessary , Enable Allogeneic , Translational Medicine , Orphan Drug Designation , Site Specific Gene Editing System , Booster Molecule , Nc ,